FDA Plays

[Do DD]

Abraxis BioScience Says Abraxane Plus Gemcitabine Increases Survival In Advanced Pancreatic Cancer In Phase I/II Study
4/18/2010 2:30 PM ET

(RTTNews) - Abraxis BioScience Inc. (ABII: News ) reported that nab-paclitaxel or Abraxane for Injectable Suspension given in combination with gemcitabine, demonstrated increased survival of the first-line treatment of patients with advanced pancreatic cancer.

The overall survival findings from a phase I/II study of nab-paclitaxel plus gemcitabine in 44 patients also showed that the combination resulted in a confirmed overall response rate in 50% of patients treated, and a disease control rate of 68%. In the overall study, three patients achieved a complete response.

The combination of nab-paclitaxel and gemcitabine is now the treatment arm of a randomized phase 3 clinical trial that is currently enrolling patients.